Immediate Impact

2 by Nobel laureates 1 from Science/Nature 36 standout
Sub-graph 1 of 17

Citing Papers

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)
2024 Standout
2 intermediate papers

Works of Inbal Golan‐Tripto being referenced

Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study
2023
Modified Tal Score: Validated score for prediction of bronchiolitis severity
2018

Author Peers

Author Last Decade Papers Cites
Inbal Golan‐Tripto 157 132 46 55 55 370
Behnaz Ansari 42 108 63 47 53 411
Patrick Stafler 245 141 79 18 36 411
Zhichun Feng 186 65 63 105 74 393
Ömer Kılıç 117 78 95 35 49 389
Lijie Gao 52 83 56 44 51 398
E Freundlich 61 78 39 49 29 300
István Szegedi 80 125 42 16 50 394
Soo Ahn Chae 82 84 62 28 47 349
H Jouan 54 51 76 53 37 312
Misao Kageyama 123 91 78 118 43 361

All Works

Loading papers...

Rankless by CCL
2026